RT Journal Article
T1 Effect of dapagliflozin on COVID-19 infection and risk of hospitalization
A1 Salgado Barreira, Ángel
A1 Seijas Amigo, Jose
A1 Rodríguez Mañero, Moisés
A1 Piñeiro Lamas, María
A1 Eiras Penas, Sonia
A1 Cordero Fort, Alberto
A1 González Juanatey, José Ramón
A1 Figueiras Guzmán, Adolfo
K1 Intensive care unit
K1 Mortality
K1 Dapaglifozin
K1 Covid-19
AB Background: Dapagliflozin has been proposed as a potential treatment for coronavirus disease 2019 (COVID-19) by reducing cytokine production and inflammation. However, there are limited data on its effectiveness. We aimed to evaluate the impact of dapagliflozin on COVID-19 severity (including hospitalization risk, ICU admission, in-hospital death and progression to severe COVID-19) and its potential on susceptibility to COVID-19 infection.Methods: We conducted a population-based case-control study. For aim 1, we assessed COVID-19 severity in cases (positive PCR patients requiring hospitalization) and matched controls (negative PCR patients or positive PCR patients not requiring hospitalization). For aim 2, we compared positive PCR cases (hospitalized and non-hospitalized) with controls. Adjusted odds ratios (aORs) were calculated using a generalized linear mixed model.Results: We analysed 86 602 subjects: 3060 were hospitalized cases, 26 757 were non-hospitalized cases and 56 785 were controls. Among the hospitalized COVID-19 patients, 228 were admitted to the ICU and 413 died. Dapagliflozin had no effect on the risk of hospitalization (aOR 0.98; 95% CI 0.65–1.48; P = 0.915), ICU admissions (aOR 1.21; 95% CI 0.34–4.25; P = 0.767) or in-hospital death (aOR 1.33; 95% CI 0.53–3.30; P = 0.543). Dapagliflozin reduced the risk of progression to severe COVID-19 by 35%, but this was not statistically significant (aOR 0.65; 95% CI 0.40–1.06; P = 0.086). Dapagliflozin was associated with a 30% increased risk of susceptibility to COVID-19 infection (aOR 1.31; 95% CI 1.05–1.62; P = 0.015).Conclusions: Use of dapagliflozin prior to SARS-CoV-2 infection was not associated with an increased risk of hospitalization, ICU admission, mortality or progression to severe COVID-19. However, it was associated with an increased risk of susceptibility to COVID-19 infection.
PB Oxford University Press
SN 0305-7453
YR 2023
FD 2023-08-07
LK https://hdl.handle.net/10347/46217
UL https://hdl.handle.net/10347/46217
LA eng
NO Salgado-Barreira, A., Seijas-Amigo, J., Rodriguez-Mañero, M., Piñeiro-Lamas, M., Eiras, S., Cordero, A., Gonzalez-Juanatey, J. R., & Figueiras, A. (2023). Effect of dapagliflozin on COVID-19 infection and risk of hospitalization. Journal of Antimicrobial Chemotherapy, 78(9), 2335–2342. https://doi.org/10.1093/jac/dkad241
NO This study was sponsored by the Carlos III Institute of Health via the ‘COV20/00470’ project (co-funded by the European Regional Development Fund, ‘A way to make Europe’). Funding for open access charge was from the Universidade de Santiago de Compostela/CISUG.
DS Minerva
RD 29 abr 2026